                Figure 3.  HIV-1 subtype B and C viruses with protease resistance mutations from individuals undergoing NFV-based HAART.Different treatment exposure periods (in months) for that drug were plotted for each subtype. Black asterisks denote significance in the difference of proportions between subtypes B and C at the 0.05 p value level.

